ANCA targeting proteinase 3 (PR3) and myeloperoxidase (MPO) are implicated in the pathogenesis of AAV, and patients who become ANCA-negative after induction therapy may have a lower risk of relapse.13 The gene discussed is PRTN3; the disease is anti-neutrophil cytoplasmic antibody-associated vasculitis.